Join to view full profile
2050 Kenny RdTower 4th FloorColumbus, OH 43221
Phone+1 614-293-4320
Fax+1 614-293-2584
Dr. Kendra is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1993 - 1998- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1990 - 1993
Rush Medical College of Rush University Medical CenterClass of 1990
Certifications & Licensure
OH State Medical License 2001 - 2026
NY State Medical License 1998 - 2002
WI State Medical License 1991 - 2001
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer Start of enrollment: 2005 Feb 25
- Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Start of enrollment: 2012 Nov 09
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Publications & Presentations
PubMed
- Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.Megan Othus, Thach-Giao Truong, Elad Sharon, Kari Kendra, Kenneth Grossmann
JCO Oncology Practice. 2026-06-23 - Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni
Journal of the National Comprehensive Cancer Network. 2026-06-01 - Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.Katie M Campbell, Daniel G Chen, Zaid E Bustami, Nataly Naser Al Deen, Egmidio Medina
Cancer Discovery. 2026-04-21
Journal Articles
- Prognostic Gene Expression Profiling in Cutaneous MelanomaDouglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Kari L..., JAMA Dermatology
Authored Content
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Press Mentions
Presurgical Pembrolizumab Beneficial for Desmoplastic MelanomaFebruary 11th, 2026- High Response to PD-1 Therapy Seen in Unresectable Desmoplastic MelanomaAugust 20th, 2025
- Immunotherapy Helps Extend the Lives of Patients with Rare Form of Skin CancerAugust 14th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
